# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-22-015548
Filing Date
2022-04-22
Accepted
2022-04-22 16:02:24
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | edge20003258x2_defa14a.htm | DEFA14A | 8967
2 |  | edge20003258x2_nc01.jpg | GRAPHIC | 700313
3 |  | edge20003258x2_nc02.jpg | GRAPHIC | 399010
| Complete submission text file | 0001140361-22-015548.txt |  | 1484222

Mailing Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138
Business Address 1030 MASSACHUSETTS AVENUE SUITE 210 CAMBRIDGE MA 02138 617-952-0555
Werewolf Therapeutics, Inc. (Filer) CIK: 0001785530 (see all company filings)

EIN.: 823523180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40366 | Film No.: 22845445
SIC: 2834 Pharmaceutical Preparations